Dental extractions on a patient with severe haemophilia A and inhibitors taking emicizumab prophylaxis. Case report and review

Oral Surgery ◽  
2021 ◽  
Author(s):  
A Hamid ◽  
N Smithson
Keyword(s):  
Case Report ◽  
Haemophilia A ◽  
Severe Haemophilia

A patient with severe haemophilia A and multiple arterial thromboses caused by large vessel vasculitis: a case report

Haemophilia ◽  
2015 ◽  
Vol 22 (1) ◽  
pp. e39-e42
Author(s):  
L. M. Vos ◽  
R. E. G. Schutgens ◽  
H. W. de Valk ◽  
W. Spiering ◽  
R. H. H. Bemelmans
Keyword(s):  
Case Report ◽  
Large Vessel Vasculitis ◽  
Large Vessel ◽  
Haemophilia A ◽  
Severe Haemophilia

scholarly journals Management of multiple myeloma in a patient with haemophilia with concurrent emicizumab – case report

2021 ◽  
Vol 8 (1) ◽  
pp. 136-140
Author(s):  
Elizabeth Davies ◽  
Luke Carter-Brzezinski ◽  
Margarita Traintafillou ◽  
Rachel Brown ◽  
Charles R M Hay
Keyword(s):  
Multiple Myeloma ◽  
Case Report ◽  
Haematological Malignancy ◽  
Standard Of Care ◽  
Bleeding Disorder ◽  
Plasma Cell Dyscrasia ◽  
Haemophilia A ◽  
Severe Haemophilia ◽  
First Line ◽  
Vte Prophylaxis

Abstract With the increased life expectancies of people with severe haemophilia A, diagnoses of disorders associated with increased age are likely to become more common. Multiple myeloma is a commonly diagnosed plasma cell dyscrasia, with incidence strongly related to age. Both the disease itself and specific myeloma therapies are associated with a significant increase in rates of venous thromboembolism (VTE). Management of VTE prophylaxis can be challenging, especially in patients with a bleeding disorder. In this case report, we describe the management of a patient with concurrent diagnosis of multiple myeloma and severe haemophilia A, undergoing first line myeloma chemotherapy. The patient was successfully managed on standard of care myeloma treatment, with use of emicizumab and venous thromboprophylaxis. This case demonstrates the successful management of a haematological malignancy and a bleeding disorder using integrated and multidisciplinary patient-focused care.

Homoeopathic Management of a Case of Severe Haemophilia Type A with Inhibitor Positive: Case Report

2020 ◽  
Vol 33 (04) ◽  
pp. 302-308
Author(s):  
Hiral Shah ◽  
Tapas Kumar Kundu ◽  
Afroz Farooque Shaikh
Keyword(s):  
Case Report ◽  
Factor Viii ◽  
Replacement Therapy ◽  
Psychological Status ◽  
Clotting Factor ◽  
Factor Viii Inhibitor ◽  
Haemophilia A ◽  
Severe Haemophilia ◽  
Clotting Factors ◽  
Bleeding Episodes

AbstractHaemophilia is an X-linked inherited immunogenetic bleeding disorder resulting from deficiency of clotting Factor VIII (haemophilia A) or Factor IX (haemophilia B). Haemophilia patients suffer from complication of developing autoantibodies/inhibitor against clotting factors used for the treatment; most commonly patients are treated with Factor VIII replacement therapy. In modern medicine, haemophiliacs with inhibitor positive status are treated with bypassing agents such as Factor VIII inhibitor bypassing agent and immune tolerance induction therapy (ITI) because such patients do not respond to traditional factor replacement therapy during an event of active bleeding. Treatment with ITI is very expensive and it requires medical expertise. Moreover, high cost of such treatment is one part of the problem, while its availability is another problem especially in developing countries. The inhibitor status among haemophilia patients is identified by conducting a blood test which measures the Bethesda units (BU) levels in the blood. In this case report, the homoeopathic management of a patient with haemophilia A severe type (Factor VIII <1%), inhibitor positive (4 BU/mL), is presented. The patient underwent treatment for a span of 4 years. After closely assessing the patient's condition and applying the principles of homeopathy medicine selection, his frequent bleeding episodes were treated with homoeopathic medicines such as Hamamelis Virginica Q, Phosphorus, Arnica montana, Rhus toxicodendron, Calendula officinalis, and Pulsatilla nigricans. Intercurrent medicine—Tuberculinum bovinum—was given when the most indicated medicine failed to relieve the symptoms of the case and was given during non-bleeding phase. The medicines not only helped in reducing haemophilia-related bleeding episodes but also improved complaints of pain, relieved skin complaints, and showed improvement in overall psychological status of patient. It can be concluded that homeopathy medicines were able to successfully reduce the frequency of bleeding and intensity of pain in this patient. Owing to reduced bleeding, he required relatively a smaller number of factor replacement treatment compared with earlier when he was not taking homeopathy. Homoeopathy proved to be effective in managing severe haemophilia patient as a supportive therapy and was able to contribute toward reduced inhibitor levels in severe haemophilia patient.

scholarly journals Dengue fever in a patient with severe haemophilia: a case report

2015 ◽  
Vol 8 (1) ◽  
pp. 78 ◽  
Author(s):  
Dilushi Wijayaratne ◽  
Priyanga Ranasinghe ◽  
Shanaka P Mohotti ◽  
Shani Dilrukshi ◽  
Prasad Katulanda
Keyword(s):  
Case Report ◽  
Dengue Fever ◽  
Haemophilia A ◽  
Severe Haemophilia

scholarly journals Case report of a fatal rectal haemorrhage in a person with severe haemophilia A receiving emicizumab and high‐dose bypassing agents in the HAVEN 1 study

Haemophilia ◽  
2020 ◽  
Vol 26 (6) ◽  
Author(s):  
Liane Khoo ◽  
Stephen Matthews ◽  
Geoffrey Kershaw ◽  
Michael Pidcock ◽  
Alex Phipps ◽  
...  
Keyword(s):  
Case Report ◽  
High Dose ◽  
Haemophilia A ◽  
Severe Haemophilia ◽  
Rectal Haemorrhage ◽  
Bypassing Agents

scholarly journals Case report of nasal pseudotumor – a rare presentation in severe haemophilia A with high titre inhibitors

2021 ◽  
Vol 8 (1) ◽  
pp. 11-14
Author(s):  
Prakas Kumar Mandal ◽  
Malini Garg ◽  
Debasis Gantait ◽  
Utpal Jana
Keyword(s):  
Case Report ◽  
Young Child ◽  
Factor Viii ◽  
Immune Tolerance ◽  
Financial Constraints ◽  
Surgical Excision ◽  
High Titre ◽  
Haemophilia A ◽  
Severe Haemophilia ◽  
Rare Presentation

AbstractHaemophilia patients with inhibitors suffer from increased morbidity and mortality due to the ineffectiveness of factor VIII replacement. Pseudotumors are rare but dangerous complications in these patients, and nasal pseudotumors are even rarer. Here, we present the case of a young child with severe haemophilia A with high titre inhibitors who developed a nasal pseudotumor. When immune tolerance therapy was not possible due to financial constraints, he was treated with FEIBA prophylaxis and rituximab. The pseudotumor was managed with surgical excision. We conclude that epistaxis in haemophiliacs can be due to an underlying nasal pseudotumor, and highlight the use of rituximab for the eradication of inhibitors.

Sign in / Sign up

Export Citation Format

Share Document